Video
Diabetic Nephropathy Inthe International Society of Nephrology and the International Diabetes Federation launched a booklet called "Diabetes in the Kidney: Time Diabetic nephropathy awareness act" [1] to highlight the global pandemic Iron industry news and advancements aawreness 2 zwareness and diabetic nephropathyy disease. Diabetic nephropathy awareness aimed to alert Gluten-free bread, health organisations, providers, doctors and Diabeitc to the increasing health and Diabetiv Diabetic nephropathy awareness Liver flush detoxification to diabetic kidney disease and its sequelae, end stage kidney disease requiring dialysis and cardiovascular death. Seven years later, the same message has become even more urgent. World Kidney Dayunder the auspices of the International Society of Nephrology ISN and the International Federation of Kidney Foundations IFKFtogether with the International Diabetes Federation IDFprovides yet another chance to underline the importance of diabetic kidney disease, stress its lack of awareness at both public and government levels and emphasise that its management involves prevention, recognition and treatment of its complications. Primary prevention of type 2 diabetes will require massive lifestyle changes in the developing and developed world supported by strong governmental commitment to promote lifestyle and societal change.Diabetic nephropathy awareness -
Reshma Kaushik, MD, FIACM, FICP; Email: reshma. kaushik rediffmail. com, , Email: reshmakaushik srhu. Abstract Introduction : Diabetic nephropathy is an important complication of diabetes mellitus leading to significant morbidity and mortality.
Keywords: Awareness , Type 2 diabetes mellitus , Diabetic nephropathy. Metrics Statistics Comments. First Name. Please enter a email address. The entered code is invalid. Generate New Image. Abstract View: Your browser does not support the canvas element. years Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec 58 34 70 96 45 71 78 84 83 90 74 98 81 51 69 79 93 95 76 75 51 56 58 50 56 73 78 74 66 87 73 73 68 37 33 29 32 34 44 41 40 58 59 41 52 PDF Download: Your browser does not support the canvas element.
years Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec 15 13 22 24 14 26 19 30 35 20 27 17 43 97 48 41 46 47 45 43 48 70 41 16 12 18 24 38 50 43 45 64 60 50 46 53 36 20 31 30 32 29 31 39 24 86 Elsevier Point of Care. Clinical Overview: Diabetic nephropathy. De Boer IH, et al.
Executive summary of the KDIGO Diabetes Management in CKD Guideline: Evidence-based advances in monitoring and treatment. Kidney International. Office of Patient Education. Chronic kidney disease treatment options. Coping effectively: A guide for patients and their families.
National Kidney Foundation. Robertson RP. Pancreas and islet cell transplantation in diabetes mellitus. Accessed May 25, Ami T. Allscripts EPSi. Mayo Clinic. June 27, Castro MR expert opinion. June 8, Chebib FT expert opinion. Mayo Clinic Press Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Mayo Clinic on Incontinence - Mayo Clinic Press Mayo Clinic on Incontinence The Essential Diabetes Book - Mayo Clinic Press The Essential Diabetes Book Mayo Clinic on Hearing and Balance - Mayo Clinic Press Mayo Clinic on Hearing and Balance FREE Mayo Clinic Diet Assessment - Mayo Clinic Press FREE Mayo Clinic Diet Assessment Mayo Clinic Health Letter - FREE book - Mayo Clinic Press Mayo Clinic Health Letter - FREE book.
Show the heart some love! Give Today. Help us advance cardiovascular medicine. Find a doctor. Explore careers. Sign up for free e-newsletters.
About Mayo Clinic. About this Site. Contact Us. Health Information Policy. Media Requests. News Network. Price Transparency. Medical Professionals. Clinical Trials. Mayo Clinic Alumni Association. Refer a Patient. Executive Health Program. International Business Collaborations. Glycemic targets: standards of medical care in diabetes— Qaseem A, Wilt TJ, Kansagara D, Horwitch C, Barry MJ, Forciea MA Clinical Guidelines Committee of the American College of Physicians.
Hemoglobin A1c targets for glycemic control with pharmacologic therapy for nonpregnant adults with type 2 diabetes mellitus: a guidance statement update from the American College of Physicians.
Ismail-Beigi F, Craven T, Banerji MA, et al. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial [published correction appears in Lancet.
Groop PH, Cooper ME, Perkovic V, Emser A, Woerle HJ, von Eynatten M. Linagliptin lowers albuminuria on top of recommended standard treatment in patients with type 2 diabetes and renal dysfunction. Groop PH, Cooper ME, Perkovic V, et al. Linagliptin and its effects on hyperglycaemia and albuminuria in patients with type 2 diabetes and renal dysfunction: the randomized MARLINA-T2D trial.
Diabetes Obes Metab. Scirica BM, Braunwald E, Raz I SAVOR-TIMI 53 Steering Committee and Investigators. Heart failure, saxagliptin and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial [published correction appears in Circulation.
Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. Fujita H, Morii T, Fujishima H, et al. The protective roles of GLP-1R signaling in diabetic nephropathy: possible mechanism and therapeutic potential.
Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. Palmer SC, Mavridis D, Nicolucci A, et al.
Comparison of clinical outcomes and adverse events associated with glucose-lowering drugs in patients with type 2 diabetes: a meta-analysis. UK Prospective Diabetes Study UKPDS Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes UKPDS 34 [published correction appears in Lancet.
Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. Barnett AH, Mithal A, Manassie J, et al. Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial.
Lancet Diabetes Endocrinol. Sarafidis PA, Bakris GL. Protection of the kidney by thiazolidinediones: an assessment from bench to bedside. Heerspink HJ, Desai M, Jardine M, Balis D, Meininger G, Perkovic V. Canagliflozin slows progression of renal function decline independently of glycemic effects.
J Am Soc Nephrol. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes— Cardiovascular disease and risk management: standards of medical care in diabetes— James PA, Oparil S, Carter BL, et al.
Whelton PK, Carey RM, Aronow WS, et al. J Am Coll Cardiol. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38 [published correction appears in BMJ.
Cushman WC, Evans GW, Byington RP, et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. Lv J, Perkovic V, Foote CV, Craig ME, Craig JC, Strippoli GF.
Antihypertensive agents for preventing diabetic kidney disease. Cochrane Database Syst Rev. The EUCLID Study Group. Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. Haller H, Ito S, Izzo JL, et al. Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes.
Fried LF, Emanuele N, Zhang JH, et al. Combined angiotensin inhibition for the treatment of diabetic nephropathy.
Currie G, Taylor AH, Fujita T, et al. Effect of mineralocorticoid receptor antagonists on proteinuria and progression of chronic kidney disease: a systematic review and meta-analysis.
BMC Nephrol. Bolignano D, Palmer SC, Navaneethan SD, Strippoli GF. Aldosterone antagonists for preventing the progression of chronic kidney disease. Menne J, Ritz E, Ruilope LM, Chatzikyrkou C, Viberti G, Haller H.
The Randomized Olmesartan and Diabetes Microalbuminuria Prevention ROADMAP observational follow-up study: benefits of RAS blockade with olmesartan treatment are sustained after study discontinuation. J Am Heart Assoc. Makani H, Bangalore S, Desouza KA, Shah A, Messerli FH. Efficacy and safety of dual blockade of the renin-angiotensin system: meta-analysis of randomised trials.
Bangalore S, Fakheri R, Toklu B, Messerli FH. Diabetes mellitus as a compelling indication for use of renin angiotensin system blockers: systematic review and meta-analysis of randomized trials [published correction appears in BMJ.
Wanner C, Krane V, März W, et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis [published correction appears in N Engl JMed.
Fellström BC, Jardine AG, Schmieder RE, et al. Rosuvastatin and cardiovascular events in patients undergoing hemo-dialysis [published correction appears in N Engl J Med.
Pedrini MT, Levey AS, Lau J, Chalmers TC, Wang PH. The effect of dietary protein restriction on the progression of diabetic and nondiabetic renal diseases: a meta-analysis. Lifestyle management: standards of medical care in diabetes— TODAY Study Group. Rapid rise in hypertension and nephropathy in youth with type 2 diabetes: the TODAY clinical trial [published correction appears in Diabetes Care.
Children and adolescents: standards of medical care in diabetes— Management of diabetes in pregnancy: standards of medical care in diabetes— Roett MA, Liegl S, Jabbarpour Y.
Diabetic nephropathy—the family physician's role. Am Fam Physician.
Iron industry news and advancements Disclosures. Please read Diabetic nephropathy awareness Disclaimer at the end of awzreness page. DIABETIC Nephropxthy DISEASE OVERVIEW. People with diabetes have a lot to Natural detoxification methods when Diabdtic comes to their health care. Having diabetes puts you at risk of other health problems, including heart attacks, strokes, vision loss, nerve damage, and kidney disease. While all of that may sound overwhelming, there is some good news; many of the steps you need to take to prevent one of those complications may actually help to prevent them all. This article will discuss the early signs of diabetic kidney disease.
Diabetic nephropathy awareness -
In later stages, symptoms may include:. Make an appointment with your health care professional if you have symptoms of kidney disease.
If you have diabetes, visit your health care professional yearly or as often as you're told for tests that measure how well your kidneys are working. A typical kidney has about 1 million filtering units.
Each unit, called a glomerulus, joins a tubule. The tubule collects urine. Conditions such as high blood pressure and diabetes harm kidney function by damaging these filtering units and tubules. The damage causes scarring. The kidneys remove waste and extra fluid from the blood through filtering units called nephrons.
Each nephron contains a filter, called a glomerulus. Each filter has tiny blood vessels called capillaries. When blood flows into a glomerulus, tiny bits, called molecules, of water, minerals and nutrients, and wastes pass through the capillary walls.
Large molecules, such as proteins and red blood cells, do not. The part that's filtered then passes into another part of the nephron called the tubule. The water, nutrients and minerals the body needs are sent back to the bloodstream.
The extra water and waste become urine that flows to the bladder. The kidneys have millions of tiny blood vessel clusters called glomeruli. Glomeruli filter waste from the blood. Damage to these blood vessels can lead to diabetic nephropathy. The damage can keep the kidneys from working as they should and lead to kidney failure.
Over time, diabetes that isn't well controlled can damage blood vessels in the kidneys that filter waste from the blood.
This can lead to kidney damage and cause high blood pressure. High blood pressure can cause more kidney damage by raising the pressure in the filtering system of the kidneys. Diabetic nephropathy kidney disease care at Mayo Clinic. Mayo Clinic does not endorse companies or products.
Advertising revenue supports our not-for-profit mission. Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press. This content does not have an English version. This content does not have an Arabic version.
Overview Diabetic nephropathy is a serious complication of type 1 diabetes and type 2 diabetes. How kidneys work. Request an appointment. Healthy kidney vs. diseased kidney Enlarge image Close. diseased kidney A typical kidney has about 1 million filtering units.
Kidney cross section Enlarge image Close. Kidney cross section The kidneys remove waste and extra fluid from the blood through filtering units called nephrons. By Mayo Clinic Staff. Show references Diabetic kidney disease. National Institute of Diabetes and Digestive and Kidney Diseases. Dunstan DW, Zimmet PZ, Welborn TA et al.
The rising prevalence of diabetes and impaired glucose tolerance: the Australian Diabetes, Obesity and Lifestyle Study.
Diabetes Care, ; 25 5 White SL, Polkinghorne KR, Cass A et al. Limited knowledge of kidney disease in a survey of AusDiab study participants.
Med J Aust, ; 4 Whaley-Connell A, Sowers JR, McCullough PA et al. Diabetes mellitus and CKD awareness: the Kidney Early Evaluation Program KEEP and National Health and Nutrition Examination Survey NHANES.
Am J Kidney Dis, ; 53 4 Suppl 4 :S Thomas M, Viberti G, Groop P. Screening for chronic kidney disease in patients with diabetes: are we missing the point? Nat Clin Pract Nephrol, ; 4 1 Holman RR, Paul SK, Bethel MA et al. N Engl J Med, ; 15 Bilous R.
Microvascular disease: what does the UKPDS tell us about diabetic nephropathy? Diabet Med, ; 25 Suppl 2 Gaede P, Lund-Andersen H, Parving HH et al. Effect of a multifactorial intervention on mortality in type 2 diabetes.
N Engl J Med, ; 6 Patel A, MacMahon S, Chalmers J et al. and ADVANCE Collaborative Group. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus the ADVANCE trial : a randomised controlled trial.
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med, ; Zoungas S, de Galan BE, Ninomiya T et al. The combined effects of routine blood pressure lowering and intensive glucose control on macrovascular and microvascular outcomes in patients with type 2 diabetes; new results from ADVANCE.
Diabetes Care, ; 32 11 Ruggenenti P, Fassi A, Ilieva AP et al. Preventing microalbuminuria in type 2 diabetes. N Engl J Med. Parving HH, Lehnert H, BrC¶chner-Mortensen J et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes.
N Engl J Med, ; 12 Lewis EJ, Hunsicker LG, Clarke WR et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Eng J Med, ; Burney B, Kalaitzidis R, Bakris G.
Novel therapies of diabetic nephropathy. Curr Opin Nephrol Hypertens, ; 18 2 Publication Dates Publication in this collection 05 Aug Date of issue Mar This work is licensed under a Creative Commons Attribution-NonCommercial 4. Sociedade Brasileira de Nefrologia Rua Machado Bittencourt, - 5ºandar - conj.
Stay informed of issues for this journal through your RSS reader. PDF English. Google Google Scholar. Versão original do texto English. Tradução automática Google Translator Microsoft Translator. Diabetic kidney disease: act now or pay later.
Blood glucose was measured by enzymatic GOD-PAP method. Serum creatinine was measured using a Jaffe kinetic method, with calibration traceable to IDMS reference material.
Fresh urine sample was collected from each participant to detect albuminuria using dipsticks COMBINA 11S, Human. The four-variable Modification of Diet in Renal Disease MDRD study equation was used to estimate glomerular filtration rate eGFR [ 20 ].
Stage 3 was further classified into 3A 45— Data were expressed as means ± standard deviation SD or percentage. Comparisons between groups were done by chi square x 2 test or t -test as appropriate. A total of patients were included in the study.
Of the participants, Mean BMI was The mean systolic and diastolic BP of the participants was Mean FBG was Mean SCr was 1. The mean eGFR was The overall prevalence of CKD stage 1—5 was Of the total participants, Only The prevalence of CKD was CKD prevalence was lower in males Overall, The proportion of individuals who were aware of their disease increased with worsening of CKD stages: 3.
Awareness for all individuals with advanced stages of CKD stage 3—5 CKD was only For logistic regression, CKD awareness was used as the outcome variable. The covariates were age, sex, duration of diabetes, family history of kidney disease, obesity, serum creatinine and albuminuria.
The prevalence of CKD of any stage [ 1 , 2 , 3 , 4 , 5 ] in our diabetic outpatients was The overall prevalence of CKD observed in our study was higher than These differences in prevalence might be because of the differences in creatinine assays and calibration, albumin assays or differences in case-mix in terms of diabetes type.
This is in accordance with other studies that found a prevalence of 3. Interestingly, only This is in accordance with our previous study, reporting only We also found that albuminuria was absent in In line with this a recent study found that approximately one half Inadequacies of CKD diagnosis in diabetes from routine clinical assessment also are mentioned frequently in the literature [ 11 , 12 , 31 ], indicating the need for a simple functional measurement of GFR, as provided using the eGFR.
Our data shows that CKD awareness rates in diabetic outpatients are low: 3. These findings complement with the ADD-CKD Study [ 13 ], in which 1. Awareness among KEEP participants with diabetes and CKD was low at 9.
Our finding of higher CKD awareness in patients with a family history of renal disease is supported by the KEEP data, which suggested that a family history of kidney disease should make CKD awareness more likely [ 35 ]. The low CKD awareness, which is magnified by the use of inadequate screening tests such as serum creatinine and dipstick albuminuria in this study, indicates that primary care physicians may not be able to identify diabetics with CKD based on the laboratory report in hand [ 13 ].
Such a finding therefore indicates the need of routine use of eGFR to improve the recognition and thus, awareness of CKD in primary care.
Currently, most laboratories in Ethiopia do not report an eGFR when renal profile or serum creatinine is ordered. As blood test for serum creatinine or urine dipstick for albuminuria are used by clinicians to determine the presence or absence of kidney disease, this form of screening can lead to underrecognition of CKD [ 11 , 31 ] and thus low disease awareness [ 36 ].
Early detection and awareness of CKD in diabetics can therefore be improved by routine eGFR reporting and primary care education on the impact of introducing eGFR into the routine screening of CKD to facilitate its early recognition and the institution of effective preventive measures for modifying disease outcomes and improving diabetes care, as shown by related studies [ 37 , 38 , 39 ].
Supporting this, a recent study noted that determination of the eGFR of even newly diagnosed asymptomatic diabetics with a view to creating awareness for early screening, evaluation and intervention would be desirable [ 40 ]. GFR can be estimated by the Cockcroft and Gault [ 41 ] or the MDRD study equations, as indicated by the NKF and the American Diabetes Association [ 42 ].
The 4-variable MDRD study equation was used for estimating GFR in this study, as recommended by the NKF KDOQI guidelines, as it generates a GFR estimation normalized to a standard body surface area 1.
Because it is more accurate than the Cockcroft-Gault equation in CKD patients with diabetes [ 43 ], and is not biased by body weight [ 44 ] and more robust when glucose control is poor [ 45 ]; the MDRD equation appears to be preferable. Additionally, the routine laboratory estimation of GFR using the simplified MDRD equation has been also shown to facilitate the recognition and documentation of early CKD and increase awareness of CKD in such patients with diabetes [ 37 , 38 ].
There is also evidence that the estimation of early GFR loss is more accurate with the MDRD equation than with the recently developed Chronic Kidney Disease Epidemiology CKD—EPI equation in diabetic population [ 46 ]. Further studies are needed to investigate whether eGFR reporting with the MDRD equation facilitates the recognition and awareness of CKD in Ethiopian diabetic adults.
This study was the first of its type to determine the prevalence and awareness of CKD among African diabetic adult outpatients but has some limitations. On the other hand, more than half We used the MDRD study equation, the validation of which is lacking among Ethiopian diabetic adults.
The CKD-EPI equation may be superior in estimating the GFR but the best eGFR equation for Ethiopian adults has not yet been determined. Finally, the measurement of serum creatinine was not standardized; this might influence the performance of eGFR equations.
In conclusion, this study demonstrated a high prevalence and low awareness of CKD among diabetic adults attending the outpatient diabetes clinic of Northeast Ethiopia. Current screening methods, serum creatinine or urine dipstick for albuminuria, underestimates the presence of clinically significant CKD in our diabetic outpatient.
More diagnostic strategies for CKD screening among diabetic adults and primary care education on the impact of detecting CKD in the early stage are needed to prevent adverse outcomes and improve diabetes care. But the data are available from the corresponding author on reasonable request.
Levey A, Atkins R, Coresh J, Cohen E, Collins A, Eckardt K-U, et al. Chronic kidney disease as a global public health problem: approaches and initiatives — a position statement from kidney disease improving global outcomes. Kidney Int.
Article CAS PubMed Google Scholar. Jha V, Garcia-Garcia G, Iseki K, Li Z, Naicker S, Plattner B, et al. Chronic kidney disease: global dimension and perspectives. Article PubMed Google Scholar.
Stanifer JW, Muiru A, Jafar TH, Patel UD. Chronic kidney disease in low- and middle-income countries. Nephrol Dial Transplant.
Article PubMed PubMed Central Google Scholar. McFarlane SI, McCullough PA, Sowers JR, Soe K, Chen S-C, Li S, et al. Comparison of the CKD Epidemiology Collaboration CKD-EPI and Modification of Diet in Renal Disease MDRD study equations: prevalence of and risk factors for diabetes mellitus in CKD in the Kidney Early Evaluation Program KEEP.
Am J Kidney Dis. Ninomiya T, Perkovic V, de Galan BE, Zoungas S, Pillai A, Jardine M, et al. Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes.
J Am Soc Nephrol. Fox CS, Matsushita K, Woodward M, Bilo HJG, Chalmers J, Heerspink HJL, et al. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis.
Laliberté F, Bookhart BK, Vekeman F, Corral M, Duh MS, Bailey RA, et al. Direct all-cause health care costs associated with chronic kidney disease in patients with diabetes and hypertension: a managed care perspective.
J Manag Care Pharm. PubMed Google Scholar. Satyavani K, Kothandan H, Jayaraman M, Viswanathan V. Direct costs associated with chronic kidney disease among type 2 diabetic patients in India.
Indian J Nephrol. Article CAS PubMed PubMed Central Google Scholar. Thomas MC, Cooper ME, Zimmet P. Changing epidemiology of type 2 diabetes mellitus and associated chronic kidney disease. Nat Rev Nephrol. Kainz A, Hronsky M, Stel VS, Jager KJ, Geroldinger A, Dunkler D, et al.
Prediction of prevalence of chronic kidney disease in diabetic patients in countries of the European Union up to Nephrol Dial Transpl. Article Google Scholar. Middleton RJ, Foley RN, Hegarty J, Cheung CM, McElduff P, Gibson JM, et al.
The unrecognized prevalence of chronic kidney disease in diabetes. Bachorzewska-Gajewska H, Malyszko J, Malyszko JS, Musial W, Dobrzycki S.
Undiagnosed renal impairment in patients with and without diabetes with normal serum creatinine undergoing percutaneous coronary intervention. Nephrology Carlton. Szczech LA, Stewart RC, Su H-L, DeLoskey RJ, Astor BC, Fox CH, et al. Primary care detection of chronic kidney disease in adults with type-2 diabetes: the ADD-CKD study awareness, detection and drug therapy in type 2 diabetes and chronic kidney disease.
PLoS One. Article PubMed PubMed Central CAS Google Scholar. KDOQI clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease.
Google Scholar. Howard K, White S, Salkeld G, McDonald S, Craig JC, Chadban S, et al. Cost-effectiveness of screening and optimal management for diabetes, hypertension, and chronic kidney disease: a modeled analysis.
Value Health. Lee SJ, Chung CW. Health behaviors and risk factors associated with chronic kidney disease in Korean patients with diabetes: the fourth Korean National Health and nutritional examination survey.
Diabetic nephropathy is a Djabetic complication of type 1 diabetes Anxiety relief for generalized anxiety disorder type 2 diabetes. It's awarenes called diabetic kidney disease. In Nephropathj United States, Iron industry news and advancements 1 in 3 people living with diabetes have diabetic nephropathy. Diabetic nephropathy affects the kidneys' usual work of removing waste products and extra fluid from the body. The best way to prevent or delay diabetic nephropathy is by living a healthy lifestyle and keeping diabetes and high blood pressure managed.
0 thoughts on “Diabetic nephropathy awareness”